David J Taggart

Title: David J Taggart: Innovator in Pharmaceutical Chemistry

Introduction

David J Taggart is a notable inventor based in Columbus, OH (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for treating viral infections and cancer. With a total of 2 patents, his work has the potential to impact various therapeutic areas.

Latest Patents

One of Taggart's latest patents is focused on Gemcitabine analogs. These analogs, including monophosphorylated variants, are designed for use in pharmaceutical compositions, kits, and treatment methods. The treatment methods encompass addressing viral infections, such as Hepatitis C Virus, and managing uncontrolled cellular proliferation, including various types of cancer like non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer, liver cancer, esophageal cancer, and lymphoma. Another significant patent involves substituted gemcitabine bicyclic amide analogs. This invention relates to the synthesis of these compounds, their pharmaceutical compositions, and methods for treating viral disorders and uncontrolled cellular proliferation.

Career Highlights

David J Taggart is currently associated with Nucorion Pharmaceuticals, Inc., where he continues to advance his research and development efforts. His work is characterized by a commitment to innovation in drug development, particularly in creating effective treatments for serious health conditions.

Collaborations

Throughout his career, Taggart has collaborated with esteemed colleagues, including Zucai Suo and Sheng Cao. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

David J Taggart's contributions to pharmaceutical chemistry through his innovative patents and collaborations highlight his role as a key figure in the field. His work continues to pave the way for advancements in treatment options for viral infections and cancer.